Subscribe
shutterstock_1635596416_sundry_photography
Sundry Photography / Shutterstock.com
1 April 2021BiotechnologyBenjamin Pelletier

The uncertain future of antibody claims

A long string of decisions from the US Court of Appeals for the Federal Circuit has undermined support for purely functional antibody epitope claims through the written description and enablement requirements of 35 USC §112.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Amgen antibody patents ‘too broad’, says Fed Circuit
16 February 2021   The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.
Big Pharma
Sanofi and C4X in $493m licensing deal
13 April 2021   UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.
Americas
Haynes Boone hires top biotech patent lawyer
19 July 2022   New partner boosts firm’s biotech practice | Move forms part of life sciences expansion | Role based at Washington, DC office.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Amgen antibody patents ‘too broad’, says Fed Circuit
16 February 2021   The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.
Big Pharma
Sanofi and C4X in $493m licensing deal
13 April 2021   UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.
Americas
Haynes Boone hires top biotech patent lawyer
19 July 2022   New partner boosts firm’s biotech practice | Move forms part of life sciences expansion | Role based at Washington, DC office.

More on this story

Americas
Amgen antibody patents ‘too broad’, says Fed Circuit
16 February 2021   The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.
Big Pharma
Sanofi and C4X in $493m licensing deal
13 April 2021   UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.
Americas
Haynes Boone hires top biotech patent lawyer
19 July 2022   New partner boosts firm’s biotech practice | Move forms part of life sciences expansion | Role based at Washington, DC office.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Pfizer infringed haemophilia therapy patent, says court